MedTrace Logo

Flavivirus Cross-priming Potential of IMOJEV

NCT03920111 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-01-31

Study results available
· View outcomes & findings →

Summary

There is a pressing need for a better experimental system to understand flavivirus antibody responses, beyond dengue, to make sure the investigators are using current vaccines to greatest effect and to inform the development of next-generation vaccines. This study will use live chimeric JE vaccine IMOJEV® as a tool for flavivirus epitope discovery. This will allow experimental JEV infection using replication competent, live, attenuated virus as a model, in a setting where the flavivirus infection history of humans can be tightly controlled.

Conditions

  • Japanese Encephalitis

Interventions

BIOLOGICAL

IMOJEV

live attenuated Japanese encephalitis (JE) vaccine IMOJEV®

Sponsors & Collaborators

  • University of Liverpool

    lead OTHER

Principal Investigators

  • Lance Turtle, Dr · University of Liverpool

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-16
Primary Completion
2021-12-23
Completion
2022-05-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03920111 on ClinicalTrials.gov